News | January 02, 2008

Abiomed Honors Tufts-New England Medical Center for Heart Recovery

January 3, 2008 – Abiomed Inc. selected Tufts-New England Medical Center (Tufts-NEMC) as a “Center of Excellence” for its cardiac program, having achieved outstanding clinical outcomes with the recovery of the native heart.

As a Center of Excellence, Tufts-NEMC will share best practices related to VAD implantation and patient care with other hospitals and medical centers. This award is granted to top institutions in the country for achieving significant clinical outcomes and their focus on recovery of the native heart. Tufts-NEMC’s outcomes are among the best in the country.

“Center of Excellence designation further exemplifies our commitment to native heart recovery and the total wellbeing of our patients,” said Afshin Ehsan, M.D., Division of Cardiothoracic Surgery at Tufts-NEMC. “Tufts-New England Medical Center’s continued success in recovering patients’ hearts, evidenced by the recovered patients able to join us today, is due to the clinical excellence and dedication of our entire cardiac team.”

Tufts-NEMC has supported more than 20 patients with Abiomed technologies. In addition, as the only Abiomed training center in New England, Tufts-NEMC conducts ongoing certification training for other hospitals.

Abiomed is a provider of medical technologies that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery, enabling the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart.

For more information: and

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init